The MEND-CABG study was a placebo controlled, randomized, double-blinded study of MC-1, designed to evaluate the potential of Medicure's lead drug in reducing ischemic damage resulting from CABG procedures. The study's primary efficacy parameter was the reduction in the composite of cardiovascular death, non-fatal myocardial infarction (heart attack) and non-fatal cerebral infarction (stroke), up to and including 30 days following CABG surgery. The study was managed by Montreal Heart Institute (MHI), together with Duke Clinical Research Institute (DCRI).
CABG is a medical procedure performed to improve blood flow to the heart by re-routing blood around the blocked artery. Due to the high incidence of coronary artery disease worldwide, as well as the effectiveness of this surgical procedure, CABG surgery is one of the 10 most frequently performed procedures in North America.
Medicure reported the results from MEND-CABG I in December 2005.
Click here to view the MEND-CABG I publication.
